Xantos Biomedicine AG Receives Funding From Sixth EU Framework Program For Angiotargeting Project
25-Feb-2005 -
Xantos Biomedicine AG announced that it has been awarded a grant from the European Commission Sixth Framework program for the discovery and validation of new targets and pathways involved in tumor induced blood vessel formation. The overall aim of the project, which will run for four years, is to ...
angiogenesis
clinical trials
Czech Republic
+6